The European Medicines Agency is close to a decision on the approval of a new corona vaccine

European Medicines Agency - EMAPhoto: AP Photo / Peter Dejong, File
Advertisements

Novavax’s corona vaccine may become the fifth vaccine to be approved in Norway and the EU. The European Medicines Agency (EMA) is approaching a decision.

“We could possibly finish the assessment before the new year. If it is approved, this vaccine will provide an additional opportunity to vaccinate people in the EU and internationally,” Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy, said at Thursday’s press conference.

Novavax’s corona vaccine Nuvaxovid is approved in Indonesia and the Philippines. The vaccine is given in two doses, administered at least 21 days apart.

The corona vaccines made by Pfizer, Moderna, AstraZeneca, and Johnson & Johnson are currently approved for use in Norway and the EU.

Next week, the EMA will consider whether the corona medicine Xevudy should be approved for the treatment of corona patients who do not need additional oxygen supply and who have an increased risk of disease progression.

Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews

Do you have a news tip for Norway Today? We want to hear it. Get in touch at info@norwaytoday.no

Advertisements

Be the first to comment on "The European Medicines Agency is close to a decision on the approval of a new corona vaccine"

Leave a comment

Your email address will not be published.


*